Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma

Medical Oncology

Volumn 15, Issue 1, 1998, Pages 44-49

  Wu, Jingjing ^a   Caliendo, Geralyn ^a   Hu, Xiao Ping ^a   Dutcher, Janice P ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Prognosis; Renal cell cancer; Sarcomatoid

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; OKT 3;

ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY SARCOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031809054     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787344     Document Type: Article

References (18)

1. The Kidney. In: Cotran RS, Kumar V, Robbins SL, Schoen F (eds) Robbins Pathological Basis of Disease. Saunders: Philadelphia 1994; pp 927-990.
2. Belldegrun A, Abi-Ada AS, Figlin RA, de Kernion JB. Renal cell carcinoma: basic biology and current approaches to therapy. Seminar in Oncology 1991; 18: 96-101.
3. Hawkins MJ. Immunotherapy with high dose interleukin 2. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds). Comprehensive Textbook of Genitourinary Oncology Williams & Wilkins: Baltimore 1996;248-255.
4. Sparano JA, Dutcher JP, Wiernik PH. Low dose interleukin 2 for advanced renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds). Comprehensive Textbook of Genitourinary Oncology 1996; pp 256-276.
5. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer 1988; 48: 7310-7313.
6. Dutcher JP et al. Outpatient subcutaneous interleukin-2 and interferon alpha for metastatic renal cell cancer: five year follow-up of the Cytokine Working Group Study. The Cancer Journal from Scientific American 1996; 157-162.
7. Sella A, Logothetis CJ, Ro JY. Sarcomatoid renal cell carcinoma: a treatable entity. Cancer 1987; 60: 1313-1316.
8. Tomera KN, Farrow GM, Lieber MM. Sarcomatoid Renal Carcinoma. The Journal of Urology 1983; 130: 657-659.
9. Farrow GM, Harrison Jr EG, Utz DC. Sarcomas and Sarcomatoid and mixed malignant tumors of the kidney in adult - Part III. Cancer 1968; 22: 556-563.
10. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 1987; 59: 516-526.
11. Noguchi S et al. Prognostic factors for metastatic renal cell cancer. Japanese Journal of Urology 1995; 86: 1279-1286.
12. Gelb AB, Shibuya RB, Weiss LM, Medeiros LJ. Stage I renal cell carcinoma. A clinicopathologic study of 82 cases. American Journal of Surgical Pathology 1993; 17: 275-286.
13. Steinberg P, Storkel S, Oesch F, Thoenes W. Carbohydrate metabolism in human renal clear cell carcinoma. Laboratory Investigations 1992; 67: 506-511.
14. Ahn YS, Zerban H, Grobholz R, Bannasch P. Sequential changes in the glycogen content, expression of glucose transporters and enzymatic patterns during development of clear/acidophilic cell tumors in rat kidney. Carcinogenesis 1992; 13: 2329-2334.
15. Kanamaru H et al. Analysis of histological heterogeneity in renal cell carcinoma: tumor size related histological change and its prognostic significance. International Journal of Urology 1996; 3: 256-260.
16. Fiori E. et al. Renal cell carcinoma in adolescents. A case report and review of the literature. Panminerva medica 1996; 38: 121-128.
17. Oleksowicz L et al. Interleukins in cancer therapy, rationale and current status. Clinical Immunotherapy 1994; 1: 271-281.
18. Stenzl A, de Kernion JB. Pathology, biology and clinical staging of renal cell carcinoma. Seminars on Oncology 1989; 16: 3-11.